ACE and COVID-19: SARS-CoV-2 determines a disruption of this ACE/ACE2 balance and activation of RAAS, which ultimately leads to the progression of COVID-19, particularly in comorbid patients (cardiovascular disease, hypertension, diabetes mellitus) [21].